Pan-antiallergy vaccine applications in environmental sustainability and healthcare
Legal Citation
Summary of the Inventive Concept
This inventive concept leverages the core technology of the pan-antiallergy vaccine to address pressing issues in environmental sustainability and healthcare, expanding its applications beyond allergy treatment.
Background and Problem Solved
The original pan-antiallergy vaccine patent, while groundbreaking, was limited to addressing allergic reactions. However, the rise of climate change, agricultural pests and diseases, skin conditions, and bee stings necessitates innovative solutions. This inventive concept tackles these challenges by adapting the core technology to new, unexplored areas.
Detailed Description of the Inventive Concept
The new claims introduce novel applications of the pan-antiallergy vaccine's protein construct. In environmental sustainability, the protein construct enhances plant carbon sequestration capabilities, mitigating climate change. In agriculture, it increases crop resistance to pests and diseases, boosting yields. In healthcare, the protein construct treats skin conditions and allergies, and even neutralizes bee venom. These applications capitalize on the vaccine's unique properties, demonstrating its versatility and potential for broader impact.
Novelty and Inventive Step
The inventive concept's novelty lies in its unexpected application of the pan-antiallergy vaccine's technology to unrelated fields, overcoming the original patent's limitations. The new claims' inventive step resides in the creative adaptation of the protein construct to tackle diverse, high-impact problems.
Alternative Embodiments and Variations
Alternative embodiments may include using the protein construct in biofuel production, enhancing soil quality, or developing diagnostic tools for environmental pollutants. Variations could involve modifying the protein construct for specific crops, skin conditions, or bee species.
Potential Commercial Applications and Market
This inventive concept has far-reaching commercial potential in the environmental sustainability, agriculture, and healthcare industries. Target markets include companies focused on climate change mitigation, agricultural technology, and pharmaceuticals, as well as government agencies and research institutions.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/395 |
| A | A61 | A61K2039/544 |
| A | A61 | A61K2039/555 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Immunology, protein engineering, and biotechnology with a focus on vaccine development and protein construct modification
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degrees in molecular biology or bioengineering, experienced in protein design, computational modeling, and immunological applications, familiar with protein scaffold manipulation and therapeutic protein development
Obviousness Rationale
A PHOSITA would recognize that the source patent's protein construct provides a versatile scaffold that can be readily adapted to multiple applications by leveraging its fundamental structural properties. The protein's modular nature inherently suggests potential for broad technological applications beyond the original allergy treatment context. The disclosed variations represent predictable extensions of the core protein engineering principles established in the source patent, utilizing standard biotechnological techniques for protein modification and application.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,623 |
|---|---|
| Title | Pan-antiallergy vaccine |
| Assignee(s) | King Abdulaziz University |